Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
This guide identifies key asset categories to hold in a new crypto portfolio, with beginner friendly risk considerations.
27,914 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A once factory-floor worker turned wealth-builder remains active in finance at age 62, choosing public transit and on...
Chip-led gains push the Nasdaq Composite higher as oil retreats and jobs data beat expectations, setting the stage fo...
As mortgage costs stay elevated, distressed properties—short sales and REOs—are quietly widening access to homeowners...
Ford’s stock surged to top the S&P 500 after a bullish Morgan Stanley note highlighted the automaker’s growing energy...
A rising number of Americans are pursuing financial independence without a six-figure salary, emphasizing budgeting, ...
Private AI secondaries are heating up as Anthropic eyes a potential IPO. Market chatter warns the scene is a pressure...
As U.S.–Iran tensions flare, energy prices surge and corporate boards adjust risk, liquidity and strategy in a newly ...
Diana Shipping (DSX) could face a volatile 2026 cycle driven by freight rates, charter activity, and balance-sheet st...
A dramatic Roland Garros moment offers real-world finance lessons. Learn how to turn focus into smart money moves wit...
A major fund boosted its Vicor stake, sending the stock higher as a 200% rally unfolds. This article unpacks the bet,...
If you’re weighing big tech bets, Microsoft often outshines Apple on value. This guide breaks down why MSFT stands as...